Skip to main content
Pharma Mar S.A. logo

Pharma Mar S.A. — Investor Relations & Filings

Ticker · PHM ISIN · ES0169501022 LEI · 959800QWKZ45ZQC2AV58 MC Manufacturing
Open in API
Filings indexed 351 across all filing types
Latest filing 2020-04-29 Director's Dealing
Country ES Spain
Listing MC PHM

About Pharma Mar S.A.

https://pharmamar.com/en/

Pharma Mar S.A. is a biopharmaceutical company specializing in the discovery, development, and commercialization of oncology treatments derived from marine sources. A pioneer in its field since 1986, the company leverages marine biodiversity to develop innovative therapies for cancer, with a particular focus on rare tumors. Its integrated R&D pipeline spans from the exploration of marine invertebrates to the marketing of approved drugs. The company maintains an extensive collection of over 500,000 marine samples, which serves as the foundation for its drug discovery programs. Key commercialized products include Yondelis® (trabectedin) for advanced soft tissue sarcoma and ovarian cancer, Zepzelca® (lurbinectedin) for small cell lung cancer, and Aplidin® (plitidepsin) for multiple myeloma.

Recent filings

Filing Released Lang Actions
Motivo de la notificación: Persona con Responsabilidad de Dirección
Director's Dealing Classification · 100% confidence The document is titled 'STANDARD FORM FOR NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM'. This form explicitly details transactions (sales/purchases) made by directors or senior management (PDMRs) of the issuer. This directly corresponds to the definition of Director's Dealing (insider trades). The filing code for this is DIRS.
2020-04-29 Spanish
La Sociedad anuncia el inicio del ensayo clínico APLICOV-PC con Aplidin® para el tratamiento de pacientes con COVID-19, que ya ha sido autorizado por la Agencia Española de Medicamentos y Productos Sa
Regulatory Filings Classification · 99% confidence The document is a formal communication addressed to the 'Comisión Nacional del Mercado de Valores' (CNMV), the Spanish securities market regulator, dated April 28, 2020. It explicitly states it is communicating 'INFORMACIÓN PRIVILEGIADA' (Inside Information) regarding the authorization by the AEMPS (Spanish Agency of Medicines and Medical Devices) to start a clinical trial (APLICOV-PC) for Aplidin® to treat COVID-19 patients. It includes a press release detailing the trial structure and scientific rationale. This type of mandatory disclosure of material, non-public information to the regulator falls under the category of general regulatory announcements, often referred to as 'Market Abuse Regulation' (MAR) disclosures in Europe. Since it is not a full Annual Report (10-K), a specific financial release (ER), or a detailed management discussion (MDA), and it is a direct regulatory filing/announcement, the most appropriate general category is Regulatory Filings (RNS). It is not a proxy statement (DEF 14A), a dividend notice (DIV), or a director's dealing report (DIRS). The document itself is the announcement, not just a notice that a report is attached (which would lean towards RPA).
2020-04-28 Spanish
La sociedad remite nota de prensa sobre los resultados del primer trimestre de 2020
Earnings Release Classification · 100% confidence The document explicitly states it presents 'resultados del primer trimestre de 2020' (first quarter 2020 results) and details key financial metrics like net profit, sales revenue, and segment performance for that period. This content structure—a summary of financial performance for a period shorter than a year—is characteristic of an Interim/Quarterly Report (IR). It is not a full Annual Report (10-K), nor is it just a brief announcement of results (ER), as it contains substantial detail. The document length (5082 chars) is sufficient for a detailed summary, ruling out RPA/RNS based on the 'MENU VS MEAL' rule for short announcements. Q1 2020
2020-04-23 Spanish
La Sociedad informa de las operaciones llevadas a cabo al amparo del Programa de Recompra de Acciones en el periodo transcurrido entre el 15 de abril y el 21 de abril de 2020.
Transaction in Own Shares Classification · 99% confidence The document is a formal communication to the 'Comisión Nacional del Mercado de Valores' (Spanish Securities Market Commission) dated April 22, 2020. The subject is 'Programas de recompra de acciones, estabilización y autocartera' (Share repurchase programs, stabilization, and treasury stock) and it details transactions conducted between April 15 and April 21, 2020, under a previously announced repurchase program. This explicitly details the company buying back its own shares. This aligns perfectly with the definition for 'Transaction in Own Shares' (Code: POS). It is not a general regulatory filing (RNS) because it fits a specific category, nor is it a Director's Dealing (DIRS) as it concerns the company itself, not individual directors.
2020-04-22 Spanish
Axesor eleva la calificación crediticia a largo plazo de Pharma Mar
Regulatory Filings Classification · 98% confidence The document is a formal communication dated April 20, 2020, addressed to the 'Comisión Nacional del Mercado de Valores' (CNMV), the Spanish securities market regulator. It explicitly states it is communicating 'INFORMACIÓN PRIVILEGIADA' (Inside Information/Privileged Information) as per Article 226 of the Securities Market Law. The content reports a specific, material event: the credit rating agency AXESOR has upgraded Pharma Mar, S.A.'s long-term credit rating from 'B+' to 'BB-' with a positive outlook. This type of mandatory disclosure of material, non-public information to the regulator is a standard regulatory filing. Since it is a specific announcement of material information that doesn't fit perfectly into ER, DIV, or DIRS, and it is a direct communication to the regulator about a material event (credit rating change), it best fits the general 'Regulatory Filings' category (RNS) as a fallback for mandatory disclosures not covered by more specific codes like 10-K or ER.
2020-04-20 Spanish
La Sociedad informa de las operaciones llevadas a cabo al amparo del Programa de Recompra de Acciones en el periodo transcurrido entre el 8 de abril y el 14 de abril de 2020.
Transaction in Own Shares Classification · 99% confidence The document is a formal communication to the Spanish National Securities Market Commission (Comisión Nacional del Mercado de Valores) dated April 15, 2020. The subject is "Programas de recompra de acciones, estabilización y autocartera" (Share repurchase programs, stabilization, and treasury stock). It details transactions executed under a previously announced share repurchase program during the period of April 8 to April 14, 2020, including tables listing the number of shares bought and the average price. This content directly relates to the company acquiring its own shares, which corresponds precisely to the definition of 'Transaction in Own Shares'.
2020-04-15 Spanish

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.